The core activity of Bioversys AG is the development and manufacture of pharmaceuticals, particularly in the field of antibiotic research and the development of therapeutics for various diseases. The company is engaged in the research and development of small molecules, peptides and therapeutic polymers and has experts in the fields of medicinal chemistry, CMC (Chemistry, Manufacturing, Control) and biotechnology on its team.
AI-generated
Offering
Products & services
Industry:Research & DevelopmentPharmaceutical Industry
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Drug research and development against antimicrobial resistance
Development of novel antibiotics with new mechanisms of action against antibiotic-resistant pathogens, in particular for severe hospital infections and other priority pathogens.
Drug research and development against tuberculosis
Development of a new anti-TB drug substance with a unique mechanism of action to potentiate ethionamide, including clinical testing in MDR-TB and TB meningitis.
Research and development of anti-virulence agents
Development of a first-in-class anti-virulence candidate against Staphylococcus aureus, including MRSA, for skin infections, pneumonia and atopic dermatitis.
Research and development against non-tuberculous mycobacterial infections
Development of a pipeline of compounds against NTM infections based on the company's proprietary ansamycin platform and the bacterial RNA polymerase target.
Drug discovery for ESKAPE pathogens
Development of small-molecule programs against important ESKAPE pathogens and other priority bacterial pathogens.